Pro-gastrin-releasing peptide, usually shortened to ProGRP, is a blood tumor marker most closely associated with small cell lung cancer (SCLC). It can help support the distinction between SCLC and other lung cancers, give a rough sense of tumor burden in some patients, and provide a convenient way to follow changes during treatment. A ProGRP result cannot diagnose lung cancer on its own, however. Tissue diagnosis, imaging, and the full clinical picture remain essential.
Interpretation also depends on the laboratory method and kidney function. Many laboratories report ProGRP in pg/mL, and commonly used assays have upper reference limits in roughly the 60–80 pg/mL range, but the exact cutoff is assay-specific. Reduced kidney function can raise ProGRP even when no SCLC is present. For that reason, the most useful question is rarely “Is this number high?” by itself. It is “How high is it, compared with this laboratory’s range, the person’s kidney function, imaging, pathology, and previous ProGRP results?”
- ProGRP is mainly used as an adjunct marker for small cell lung cancer, especially for diagnosis support and treatment monitoring.
- A high ProGRP result does not prove cancer. Kidney impairment and some other neuroendocrine tumors can also raise the level.
- Reference limits vary by assay. Some modern assays place the upper reference limit around 60–80 pg/mL, so use the range printed on the report.
- Falling ProGRP during effective therapy is generally reassuring when the marker was elevated at baseline; a sustained rise can prompt evaluation for progression or relapse.
- ProGRP does not replace biopsy or imaging. It is best interpreted alongside pathology, CT or PET findings, symptoms, and other laboratory data.
Table of Contents
- What the ProGRP Test Measures
- Why ProGRP Is Used in Small Cell Lung Cancer
- ProGRP Reference Range and High Results
- Kidney Function and Other Causes of High ProGRP
- ProGRP for Treatment Monitoring
- How the Test Is Done and How to Prepare
- How to Interpret ProGRP With Other Tests
What the ProGRP Test Measures
ProGRP is a stable precursor-related peptide derived from gastrin-releasing peptide. Gastrin-releasing peptide itself is biologically active but unstable in blood, which makes it difficult to use as a routine laboratory marker. ProGRP is more stable and can be measured reliably in serum or plasma with immunoassays.
The marker is especially relevant to neuroendocrine cells. Small cell lung cancer has strong neuroendocrine features, and many SCLC tumors release ProGRP into the circulation. This is why ProGRP has become one of the better-known serum markers for SCLC.
A ProGRP blood test answers a biochemical question: how much measurable ProGRP is circulating at the time the sample is taken? It does not show where a tumor is, prove that a lung mass is malignant, or establish a cancer stage. Those questions require imaging and tissue evaluation.
ProGRP can be useful in several settings:
- supporting suspicion of SCLC when a lung lesion has been found;
- helping distinguish SCLC from many non-small cell lung cancers when interpreted with other findings;
- establishing a pretreatment baseline;
- following response during systemic therapy if the pretreatment level was elevated;
- adding context when recurrence or progression is suspected.
The strongest value usually comes from serial measurement, not from one isolated number. A marker that starts high and then changes substantially with the clinical course can become a useful individualized signal for that patient.
Why ProGRP Is Used in Small Cell Lung Cancer
Small cell lung cancer is an aggressive neuroendocrine carcinoma that often grows and spreads quickly. Diagnosis still requires histologic or cytologic confirmation whenever feasible, but blood markers can add useful information before and after diagnosis.
ProGRP is relatively specific for the small-cell phenotype compared with several older lung tumor markers. Across studies, it tends to be elevated more often in SCLC than in non-small cell lung cancer, although sensitivity is not high enough for the test to rule out SCLC when the result is normal.
That distinction matters. A normal ProGRP does not exclude SCLC. Some confirmed SCLC tumors release little ProGRP, and marker secretion can vary by tumor biology and burden. Conversely, an elevated ProGRP increases suspicion but is not specific enough to establish the diagnosis without pathology.
In practical terms, clinicians may use ProGRP as one piece of a larger diagnostic picture that includes:
- symptoms such as persistent cough, breathlessness, chest pain, weight loss, or neurologic symptoms;
- chest imaging showing a suspicious central or hilar lung mass, lymphadenopathy, or distant disease;
- bronchoscopy, needle biopsy, or another tissue-sampling method;
- pathology showing small-cell morphology and neuroendocrine differentiation;
- other laboratory markers, sometimes including neuron-specific enolase (NSE).
ProGRP can also correlate with disease extent. Higher concentrations are seen more often in patients with larger tumor burden or more advanced disease, but there is too much overlap between individuals to use a single level as a formal stage. A person with a modest elevation can still have important disease, and a person with a very high value may have contributing renal impairment.
For that reason, ProGRP should be described as an adjunctive tumor marker, not as a stand-alone cancer test.
ProGRP Reference Range and High Results
There is no universal ProGRP “normal range” that applies to every laboratory. Different assays use different antibodies, calibrators, sample types, and reference populations. Always interpret the value against the reference interval printed on the specific laboratory report.
For perspective, one widely used automated assay has reported healthy-population upper percentiles in approximately the 60–80 pg/mL range depending on whether serum, lithium-heparin plasma, or EDTA plasma is tested. Older studies and other methods have used cutoffs near 50 pg/mL. These numbers are not interchangeable.
A practical way to think about results is shown below.
| Result pattern | What it may mean | Typical next step |
|---|---|---|
| Within the laboratory reference range | SCLC is less likely to be producing substantial ProGRP, but SCLC is not excluded. | Use imaging and pathology if cancer is suspected. |
| Mild elevation | Could reflect SCLC, another neuroendocrine tumor, renal impairment, or assay-related variation. | Review kidney function, clinical context, and whether the result persists. |
| Marked elevation | Raises stronger concern for a ProGRP-secreting neuroendocrine malignancy, particularly SCLC, but remains non-diagnostic. | Correlate promptly with imaging, pathology, and renal function. |
| Falling level during treatment | Often parallels tumor response when baseline ProGRP was elevated. | Continue planned clinical and radiologic response assessment. |
| New sustained rise after response | May suggest renewed tumor activity or relapse. | Reassess trend, symptoms, kidney function, and imaging. |
A high value should therefore be interpreted in degrees and in context. The difference between a result just above the upper limit and a result many times above that limit may matter clinically, but there is no single concentration that proves SCLC for every assay and every patient.
It is also important to compare like with like. When monitoring over time, using the same laboratory and assay whenever possible reduces method-related variation. If a laboratory platform changes, the old and new values may not be directly comparable.
Kidney Function and Other Causes of High ProGRP
Kidney function is one of the most important confounders in ProGRP interpretation. ProGRP is cleared in part through the kidneys, so reduced glomerular filtration can cause the concentration to rise. The effect becomes especially important in moderate to severe chronic kidney disease and can create a false impression of tumor-marker elevation.
When ProGRP is unexpectedly high, clinicians commonly review creatinine and estimated glomerular filtration rate (eGFR). A mild elevation in a person with substantially reduced eGFR deserves much more caution than the same result in someone with normal kidney function.
Several other situations can also produce elevated ProGRP. These include other neuroendocrine neoplasms, such as pulmonary carcinoids, large-cell neuroendocrine carcinoma, medullary thyroid carcinoma, and some extrapulmonary neuroendocrine carcinomas. Research has also described ProGRP elevations in certain other cancers with neuroendocrine differentiation.
This explains why a high value should not automatically be translated into “small cell lung cancer.” The marker is associated with SCLC, but it is not anatomically specific to the lung and it is not cancer-exclusive.
Potential reasons for a high ProGRP result include:
- small cell lung cancer;
- another pulmonary or extrapulmonary neuroendocrine neoplasm;
- reduced kidney function;
- less commonly, another malignancy with neuroendocrine features;
- laboratory or pre-analytical variation.
The pattern of the result matters. A persistently and substantially elevated ProGRP in a person with suspicious chest imaging and normal kidney function carries different meaning from a borderline elevation discovered incidentally in advanced chronic kidney disease.
ProGRP for Treatment Monitoring
ProGRP can be especially useful when it is elevated before treatment. In that situation, the baseline acts as a personal reference point. Studies of patients receiving chemotherapy have shown that ProGRP often declines quickly when SCLC responds, sometimes within the first treatment cycles.
A large percentage drop can support other evidence of response, but it does not replace CT scans or other response assessment. Imaging remains necessary because tumor markers can fall without complete disease control, and some lesions may behave differently from the overall circulating-marker trend.
During monitoring, clinicians are usually interested in three patterns.
A clear fall after treatment begins
A pronounced decline is generally favorable when it matches improving symptoms and radiologic response. The exact percentage considered meaningful varies by study and assay. It is better to focus on the overall trajectory than to apply a universal percentage cutoff.
A plateau or failure to fall
If ProGRP was clearly elevated at diagnosis and changes little after treatment starts, the result may raise concern for limited response. It should prompt review of imaging and the rest of the clinical picture rather than trigger a treatment change by itself.
A renewed rise after a prior response
A sustained increase can precede or accompany radiologic progression in some patients. Before interpreting a rise as relapse, clinicians should confirm the trend and check for changes in kidney function or laboratory method.
ProGRP is less useful for monitoring when the pretreatment result was normal or only minimally elevated. A marker that the tumor did not produce at baseline cannot be expected to track that tumor reliably later.
The most defensible monitoring strategy is therefore individualized: establish whether the marker is informative at diagnosis, repeat it at clinically meaningful intervals, and interpret it with scans, symptoms, treatment timing, and renal function.
How the Test Is Done and How to Prepare
ProGRP is measured from a standard blood sample. Depending on the laboratory, the specimen may be serum or a specific type of plasma. No special diet is usually required, and fasting is generally not necessary unless other tests being drawn at the same time require it.
Preparation is mostly about making sure the result can be interpreted correctly:
- tell the clinician about known kidney disease;
- make sure recent creatinine or eGFR results are available when relevant;
- use the same laboratory for serial monitoring when practical;
- note whether the blood draw occurred before treatment, during a treatment cycle, or after therapy;
- mention major changes in health that could affect renal function, such as dehydration, acute illness, or hospitalization.
The blood draw itself carries the usual minor risks of venipuncture, such as temporary discomfort, bruising, or rarely lightheadedness.
ProGRP is not a screening test for healthy people. There is no evidence-based role for ordering it as a general cancer screen in someone without symptoms, suspicious imaging, or a relevant known malignancy. A nonspecific elevation in that setting can lead to unnecessary scans and anxiety without reliably detecting early SCLC.
How to Interpret ProGRP With Other Tests
The most accurate interpretation combines ProGRP with the tests that answer different parts of the diagnostic question.
Imaging locates disease. Chest CT identifies the primary lung lesion, mediastinal nodes, and many thoracic abnormalities. PET/CT, brain MRI, or other studies may be used for staging depending on the clinical situation.
Pathology establishes the diagnosis. A biopsy can confirm SCLC and distinguish it from non-small cell lung cancer or another neuroendocrine neoplasm. This remains the key diagnostic step whenever tissue can be obtained safely.
Other blood markers may add context. NSE is another commonly studied SCLC marker. ProGRP often has better specificity, while NSE can be affected by hemolysis and other non-cancer causes. Some clinicians measure both because the markers can complement each other, but neither replaces pathology.
Kidney tests prevent misinterpretation. Creatinine and eGFR are particularly important when a ProGRP elevation is modest or unexpected.
A useful way to interpret a result is to ask four questions:
- Was ProGRP elevated before treatment or at the time of suspected diagnosis?
- Is kidney function normal enough for the result to be trusted without major adjustment in interpretation?
- Does the direction of change match symptoms and imaging?
- Is the same assay being used over time?
When those answers line up, ProGRP can be a practical marker of disease activity. When they do not, clinicians should avoid treating the laboratory number as if it were a diagnosis.
Seek prompt medical assessment for symptoms that may reflect significant lung disease or cancer progression, including new or worsening shortness of breath, coughing up blood, severe chest pain, new neurologic deficits, marked weakness, or rapidly worsening general condition. These symptoms require clinical evaluation regardless of the ProGRP value.
A practical way to interpret serial ProGRP is to compare each result with the patient’s own pretreatment baseline rather than with an isolated population cutoff. A large decline during therapy can support response when scans and symptoms are also improving. If the concentration later rises on two measurements, clinicians consider whether the change is larger than expected analytical variation and whether kidney function has changed. A new reduction in glomerular filtration can raise ProGRP even when the tumor is stable, so creatinine and estimated glomerular filtration rate are useful companion results.
The timing of blood draws should also be consistent when possible. Chemotherapy, hydration changes, acute illness, and laboratory platform changes can complicate trends. If a patient changes hospitals, the new laboratory may use a different assay with a different reference interval. Establishing a new baseline may be more reliable than directly comparing values from unlike methods.
ProGRP is most informative when it answers a focused question: does the biochemical trend agree with the clinical course of a known small cell lung cancer? It should not delay imaging when symptoms suggest progression, and it should not be used to declare remission when scans or examination remain concerning.
A stable result is most reassuring when it agrees with stable symptoms and imaging.
References
- Progastrin-Releasing Peptide As a Diagnostic Biomarker of Pulmonary and Non-Pulmonary Neuroendocrine Neoplasms 2024 (Review)
- Small Cell Lung Carcinoma: Current Diagnosis, Biomarkers, and Treatment Options with Future Perspectives 2023 (Review)
- Evaluating the diagnostic and prognostic value of serum TuM2‐PK, NSE, and ProGRP in small cell lung cancer 2023
- Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission 2023
- A comparative study of ProGRP and CEA as serological markers in small cell lung cancer treatment 2024
- Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2021 (Guideline)
Disclaimer
This article is for general educational purposes and does not diagnose or rule out small cell lung cancer. ProGRP reference limits and clinical meaning vary by assay and kidney function, so results should be interpreted by a clinician together with imaging, pathology, symptoms, and other laboratory findings. Seek urgent medical care for severe breathing difficulty, coughing up significant blood, new neurologic symptoms, or other rapidly worsening symptoms.
